Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

NCT07101159 | Not Yet Recruiting Phase 2

• 1 other identifier: OBU-BC-II-304
• Study Type: interventional
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study aims to evaluate the efficacy and safety of adjuvant endocrine therapy combined with dalpiciclib at different doses and durations in patients with hormone receptor (HR)-positive, HER2-negative early-stage breast cancer. It is a multicenter, prospective clinical study. All enrolled patients will receive either dalpiciclib 125 mg for 2 years or dalpiciclib 100 mg for 3 years, in combination with standard endocrine therapy. The primary endpoint is 3-year invasive disease-free survival (iDFS).

Conditions

Early Breast Cancer; Adjuvant Therapy; Hormone Receptor Positive / HER2-negative Breast Cancer

Keywords

dalpiciclib; hormone receptor positive/HER2-negative breast cancer; early breast cancer

Outcome Measures

Primary Outcomes (1)

• 3-years Invasive Disease-Free Survival (iDFS)

  36 months from randomization

Secondary Outcomes (4)

• Distant Disease-Free Survival (DDFS)

  Up to 48 months

• Overall Survival (OS)

  up to 48 months

• Incidence and Severity of Adverse Events

  From treatment initiation to 30 days after the last dose, up to approximately 36 months

• Patient-Reported Outcomes (PROs)

  Baseline to end of follow-up (up to 48 months)

Study Arms (2)

2-Year Dalpiciclib 125 mg + Endocrine Therapy

EXPERIMENTAL

Patients will receive dalpiciclib 125 mg orally once daily on days 1-21 of a 28-day cycle for 2 years, in combination with standard endocrine therapy.

Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane); Drug: Dalpiciclib

3-Year Dalpiciclib 100 mg + Endocrine Therapy

EXPERIMENTAL

Patients will receive dalpiciclib 100 mg orally once daily on days 1-21 of a 28-day cycle for 3 years, in combination with standard endocrine therapy.

Drug: Dalpiciclib; Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)

Interventions

Dalpiciclib DRUG

Dalpiciclib 100 mg orally, daily on days 1-21 of a 28-day cycle, for 3 years.

3-Year Dalpiciclib 100 mg + Endocrine Therapy

Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) DRUG

Standard adjuvant endocrine therapy (e.g., tamoxifen or aromatase inhibitor), as per physician's choice.

2-Year Dalpiciclib 125 mg + Endocrine Therapy; 3-Year Dalpiciclib 100 mg + Endocrine Therapy

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female breast cancer patients aged ≥ 18 years, who are postmenopausal or premenopausal/perimenopausal;
• Histologically confirmed HR-positive, HER2-negative early-stage breast cancer (immunohistochemical detection shows ER ≥ 10% and/or PR ≥ 10%, HER2 0-1+ or HER2 ++ but negative and non-amplified by FISH or CISH detection);
• Histologically confirmed invasive breast cancer with postoperative pathological stage II-III;
• Patients with or without prior neoadjuvant chemotherapy or adjuvant chemotherapy are eligible for enrollment;
• The maximum time from surgery to enrollment does not exceed 12 months;
• Patients receiving radiotherapy must have recovered from acute radiation reactions, with a washout period of at least 14 days from the end of radiotherapy to enrollment;
• Patients who received previous chemotherapy must have recovered from acute adverse reactions of chemotherapy (graded ≤ 1 according to \[CTCAE\]) before enrollment, except for alopecia or grade 2 peripheral neuropathy. There must be a washout period of at least 21 days from the last chemotherapy administration to enrollment;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
• The main organ function levels must meet the following requirements: Blood routine: Neutrophil count (ANC) ≥ 1.5×10⁹/L; Platelet count (PLT) ≥ 90×10⁹/L; Hemoglobin (Hb) ≥ 90 g/L;Blood biochemistry: Total bilirubin (TBIL) ≤ 2.5×ULN; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5×ULN; Alkaline phosphatase ≤ 2.5×ULN; Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5×ULN;
• lead electrocardiogram: Fridericia-corrected QT interval (QTcF) \< 470 ms in females (QTcF calculation formula: QTcF = QT/(RR\^1/3));
• Voluntarily participate in this study, sign the informed consent, have good compliance and are willing to cooperate with follow-up.

You may not qualify if:

• Stage IV breast cancer, recurrent or metastatic breast cancer, or inflammatory breast cancer;
• A history of any malignant tumor, or having received anti-tumor treatment or radiotherapy for any malignant tumor in the past, excluding cured malignant tumors such as carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin;
• Concurrent participation in other clinical trials;
• Having received blood transfusion or treatment with colony-stimulating factors, etc. within 2 weeks before enrollment;
• Known history of allergy to the components of the drugs in this protocol;
• History of immunodeficiency, including positive HIV test, or suffering from other acquired or congenital immunodeficiency diseases, or having a history of organ transplantation;
• A history of any heart disease, including: angina pectoris; arrhythmia requiring drug treatment or with clinical significance; myocardial infarction; heart failure; any other heart disease judged by the researcher as unsuitable for participating in this trial;
• Pregnant or lactating female patients;
• Any other conditions that the researcher deems make the subject unsuitable for participating in this study.

Sponsors & Collaborators

• Fujian Cancer Hospital: lead

MeSH Terms

Conditions

Breast Neoplasms

Interventions

dalpiciclib; Tamoxifen; Anastrozole; Letrozole; exemestane

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Stilbenes; Benzylidene Compounds; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Nitriles; Triazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Central Study Contacts

Chuangui Song

CONTACT

+86 13960709993; songchuangui@yahoo.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 25, 2025
• First Posted: August 3, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): December 1, 2031
• Study Completion (Estimated): December 1, 2031
• Last Updated: August 3, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share